TMCnet News
Isonics Corporation to Present at Southern California Investment Association Conference GOLDEN, Colo. --(Business Wire)-- June 4, 2004 -- VP Dr. Hans J. Walitzki to Update West Coast Investment Community on Recent Developments in Company's Semiconductor, Life Sciences and Homeland Security InitiativesIsonics Corporation (Nasdaq:ISON), a leader in the development of isotopically engineered and nano-structured materials, a supplier of silicon-on-insulator (SOI) wafers to the semiconductor industry and isotopes for life sciences and health care applications, announced today that the Company will be presenting at the Southern California Investment Association (SCIA) Conference tomorrow, Saturday, June 5, at the John Wayne Hilton in Newport Beach, California. SCIA was founded to facilitate stock support and capital formation for select companies. SCIA is a national alliance of more than one hundred NASD member firms, investment bankers, investment advisors, analysts, capital formation services, investor relations, industry consultants, securities attorneys, media and accredited investors. The organization's goal is to assist its member network and to build exposure and support for small-to-medium listed and emerging-growth companies by providing a bimonthly forum. SCIA's forum showcases cutting-edge national and international presenting companies. James E. Alexander, Isonics' president and CEO, said, "We look forward to the opportunity to address the 'Tech Coast' investment community in Southern California tomorrow. We are excited to be able to present recent company developments, as well as our strategic vision for moving forward. By employing nanotechnological processes, we believe our semiconductor business will produce value-added products and technology for an industry hungry to improve performance and margins. This is a perfect forum for which to tell our story." About Isonics Corporation Isonics Corporation has three business divisions: (1) Isonics Semiconductor, (2) Isonics Life Sciences, and (3) Homeland Security. Isonics is a world leader in isotopically engineered materials and through its semiconductor division produces isotopically pure silicon-28 chemicals and wafers for the semiconductor industry. Through advances in nanotechnology, the Company is also focused on research and development opportunities for further, value-added product and application development. Isonics' Life Sciences division markets and sells stable isotopes for the health care industry such as carbon-13 for diagnostic breath tests and drug design, and radioisotopes and stable isotopes, such as oxygen-18 for positron emission tomography (PET) imaging. Stable isotopes can be thought of as ultra pure materials. This high degree of purification provides enhanced properties as compared to natural materials. Our efforts in the Homeland Security segment are nascent at the present time as we proceed to develop further our neutron-based detection technology. Additional information may be obtained at the Company's Web site at http://www.isonics.com. Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's 10-KSB for the year ended April 30, 2003, and its quarterly report on Form 10-QSB for the nine months ended January 31, 2004, both as filed with the Securities and Exchange Commission, which include the Company's cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission. |
